A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd). The ...
AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...
The Baltimore Sun welcomes submissions of op-ed articles of 650 to 750 words. Local topics and authors are preferred. Please submit them by using this form or emailing [email protected].
OB/Gyn News, opinions and meeting coverage in obstetrics and gynecology. See All in OB/Gyn Abortion Breast Cancer Cervical Cancer Fibroids General OB/GYN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results